Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2023-02-27 00:00:00 ET · period of report 2023-02-23 · accession 0001209191-23-013470 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-27 | 2023-02-24 | ACAD | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $18.78 | -577 | 4,118 | -12% | -$10.8K |
| D | 2023-02-27 | 2023-02-23 | ACAD | Schneyer Mark C. | EVP, CFO | M - OptEx | — | +1,353 | 4,695 | +40% | — |
| D | 2023-02-27 | 2023-02-23 | ACAD | Schneyer Mark C. | EVP, CFO | M - OptEx | $0.00 | -1,353 | 2,706 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-24 | S | D | 577 | $18.78 | 4,118 | D | — | — | |
| 2 | Common | Common Stock | 2023-02-23 | M | A | 1,353 | — | 4,695 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| 3 | Derivative | Restricted Stock Units | 2023-02-23 | M | D | 1,353 | $0.00 | 2,706 | D | — · — to — | 1,353 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F3) The restricted stock units vest in four equal annual installments beginning February 23, 2022. |